scholarly journals Determination of Potential Drug–Drug Interactions Using Various Software Programs in a Community Pharmacy Setting

2019 ◽  
Vol 16 (1) ◽  
pp. 14-19
Author(s):  
Mesut SANCAR ◽  
Aksa KAŞIK ◽  
Betul OKUYAN ◽  
Sevda BATUHAN ◽  
Fikret Vehbi İZZETTİN
Keyword(s):  
Drug Interactions ◽  
Community Pharmacy ◽  
Potential Drug ◽  
Software Programs ◽  
Pharmacy Setting

scholarly journals Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital

Pharmaceutics ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 713
Author(s):  
Gracia Santos-Díaz ◽  
Ana María Pérez-Pico ◽  
Miguel Ángel Suárez-Santisteban ◽  
Vanesa García-Bernalt ◽  
Raquel Mayordomo ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Drug Interactions ◽  
Cross Sectional Study ◽  
Potential Drug ◽  
Cross Sectional ◽  
Major Health Problem ◽  
Major Health ◽  
Spanish Hospital

Chronic kidney disease (CKD) is a major health problem worldwide and, in Spain, it is present in 15.1% of individuals. CKD is frequently associated with some comorbidities and patients need to be prescribed multiple medications. Polypharmacy increases the risk of adverse drug reactions (ADRs). There are no published studies evaluating the prevalence of potential drug–drug interactions (pDDIs) among CKD patients in any European country. This study was aimed to determine the prevalence, pattern, and factors associated with pDDIs among CKD patients using a drug interactions program. An observational cross-sectional study was carried out at Plasencia Hospital, located in Spain. Data were collected among patients with CKD diagnoses and pDDIs were assessed by the Lexicomp® Drug Interactions platform. Data were obtained from 112 CKD patients. A total number of 957 prescribed medications were acknowledged, and 928 pDDIs were identified in 91% of patients. Age and concomitant drugs were significantly associated with the number of pDDIs (p < 0.05). According to the results, the use of programs for the determination of pDDIs (such as Lexicomp®) is recommended in the clinical practice of CKD patients in order to avoid serious adverse effects, as is paying attention to contraindicated drug combinations.

A Review of Drug Interactions With Psychiatric Medicines for the Pharmacy Practitioner

2007 ◽  
Vol 20 (4) ◽  
pp. 327-333 ◽  
Author(s):  
Eric C. Kutscher ◽  
Bruce Alexander
Keyword(s):  
Cytochrome P450 ◽  
General Population ◽  
Drug Interactions ◽  
Clinical Effect ◽  
Computer Software ◽  
Potential Drug ◽  
Cytochrome P450 Enzymes ◽  
Over The Counter ◽  
Software Programs

With thousands of potential drug interactions, it is next to impossible to remember them all, especially with many people on multiple prescriptions and over-the-counter medications. With the increasing use of psychiatric medicines in the general population, drug interactions may occur without recognition or warning. Pharmacy computer software programs provide help with identifying the majority of potential drug interactions, but these systems are only as good as the user who develops them. Some drug interactions are negligible, whereas others are quite significant. It is most important to remember drug interactions that may have a significant clinical effect. Approximately half of all medications prescribed today are affected by cytochrome P450 enzymes, but other interactions that involve various mechanisms can also be problematic. This review identifies drug interactions that may occur with the most frequently prescribed psychiatric medications and provides a review of selected interactions that may be clinically relevant for the pharmacist to review.

scholarly journals Statin drug-drug interactions in a Romanian community pharmacy

2016 ◽  
Vol 89 (2) ◽  
pp. 273-278 ◽  
Author(s):  
Raluca Badiu ◽  
Camelia Bucsa ◽  
Cristina Mogosan ◽  
Dan Dumitrascu
Keyword(s):  
Drug Interaction ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Community Pharmacy ◽  
Safety Profile ◽  
Potential Drug ◽  
Online Program ◽  
High Prevalence ◽  
Statin Drug

Background and aim. Statins are frequently prescribed for patients with dyslipidemia and have a well-established safety profile. However, when associated with interacting dugs, the risk of adverse effects, especially muscular toxicity, is increased.The objective of this study was to identify, characterize and quantify the prevalence of the potential drug-drug interactions (pDDIs) of statins in reimbursed prescriptions from a community pharmacy in Bucharest.Methods. We analyzed the reimbursed prescriptions including statins collected during one month in a community pharmacy. The online program Medscape Drug Interaction Checker was used for checking the drug interactions and their classification based on severity: Serious – Use alternative, Significant – Monitor closely and Minor.Results. 132 prescriptions pertaining to 125 patients were included in the analysis. Our study showed that 25% of the patients who were prescribed statins were exposed to pDDIs: 37 Serious and Significant interactions in 31 of the statins prescriptions. The statins involved were atorvastatin, simvastatin and rosuvastatin.Conclusions. Statin pDDIs have a high prevalence and patients should be monitored closely in order to prevent the development of adverse effects that result from statin interactions.

Potential drug–drug interactions between anti-cancer agents and community pharmacy dispensed drugs

2010 ◽  
Vol 32 (5) ◽  
pp. 575-580 ◽  
Author(s):  
Marsha L. Voll ◽  
Kim D. Yap ◽  
Wim E. Terpstra ◽  
Mirjam Crul
Keyword(s):  
Drug Interactions ◽  
Community Pharmacy ◽  
Potential Drug ◽  
Anti Cancer

OTC Orlistat Poses Potential Drug Interactions

2006 ◽  
Vol 36 (4) ◽  
pp. 8
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Drug Interactions ◽  
Potential Drug
Sign in / Sign up

Export Citation Format

Share Document